Date: 2013-05-13
Type of information: Fundraising
Company: Neovacs (France)
Investors: OSEO (France)
Amount: €414,839
Funding type:
Planned used: This payment supports Tracker, a development project with its TNF-Kinoid drug candidate for rheumatoid arthritis.
Others: Neovacs, a leader in active immunotherapies for the treatment of autoimmune diseases, has received €414,839 from the French Innovation agency Oséo following achievement of a third milestone in early April, in accordance with the schedule agreed between the parties as part of the Tracker Project in rheumatoid arthritis (RA). The Oséo funding for the project totals €6.4 million for Neovacs, of which €3.5 million have already been received (including the current payment).
Last November, Neovacs has presented Month 6 follow–up results of its TNF–Kinoid Phase II study in rheumatoid arthritis in a poster during the Annual Meeting of the American College of Rheumatology on November 11, 2012 in Washington,DC. A phase 2b study of TNF-Kinoid in rheumatoid arthritis is now expected to start in mid 2013.
Therapeutic area: Autoimmune diseases – Inflammatory diseases - Rheumatic diseases
